HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Qingdao Haier Biomedical  Lt / Equity Bottom-Up

Recently, <a href="https://www.smartkarma.com/entities/qingdao-haier-biomedical-co-ltd-a" target="_blank" data-smartkarma-citation="entities:30352:1" rel="noopener">Qingdao Haier Biomedical Co., Ltd.-A (688139 CH)</a> released the performance announcement in 2020. Haier is expected to achieve the net income attributed to shareholders in 2020 of RMB379 million to RMB425 million, up 3713% to 3994% YoY. The Company's non-recurring profit and loss increased largely YoY due to the disposal of subsidiary as well as the increase in financing income. Net income after deducting non-recurring gains and losses is expected to reach RMB312 million to RMB354 million, up 87% to 112% YoY. Meanwhile, in 2020Q4, net income attributed to shareholders is expected to be RMB107 to RMB152 million, up 119.11%-212.54% YoY. Net income after deducting non-recurring gains and losses is expected to reach RMB90 million to RMB132 million, up 84.18% to 169.47% YoY. The results beat the market expectations.

Recently, Qingdao Haier Biomedical Co., Ltd.-A (688139 CH) released the performance announcement in 2020. Haier is expected to achieve the net income attributed to shareholders in 2020 of RMB379 million to RMB425 million, up 3713% to 3994% YoY. The Company's non-recurring profit and loss increased largely YoY due to the disposal of subsidiary as well as the increase in financing income. Net income after deducting non-recurring gains and losses is expected to reach RMB312 million to RMB354 million, up 87% to 112% YoY. Meanwhile, in 2020Q4, net income attributed to shareholders is expected to be RMB107 to RMB152 million, up 119.11%-212.54% YoY. Net income after deducting non-recurring gains and losses is expected to reach RMB90 million to RMB132 million, up 84.18% to 169.47% YoY. The results beat the market expectations.

Haier Biomedical (688139.CH) - Just Been Included in the FTSE GEIS, Time to Follow

Thematic (Sector/Industry)

1. Industry viewpoints:<ul>
<li>The official document about the 4th volume-based purchase (VBP) was issued to clarify the relevant varieties and rules, and the bidding will start on February 3rd, 2021.</li>
<li>Biobanks and vaccines are the main driving force for the overall cryogenic storage market to continue to grow at a high rate in the future.</li>
<li>Currently, the “AI + medical” industry is in a period of rapid growth.</li>
</ul>2. Company news:News about the progress of innovative medical device, new drugs and new licensing agreement from <a href="https://www.smartkarma.com/entities/venus-medtech-hangzhou-inc" target="_blank" data-smartkarma-citation="entities:28257:1" rel="noopener">Venus MedTech (2500 HK)</a>, <a href="https://www.smartkarma.com/entities/gracell-biotechnologies-inc" target="_blank" data-smartkarma-citation="entities:31108:1" rel="noopener">Gracell Biotechnologies Inc (GRCL US)</a>, <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, and <a href="https://www.smartkarma.com/entities/alphamab-oncology" target="_blank" data-smartkarma-citation="entities:28213:1" rel="noopener">Alphamab Co Ltd (9966 HK)</a>.3. Market review: Last week, stock price for healthcare sector in A share increased 7.79%, while CSI 300 increased 2.05% over the same period of time.4. Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
The official document about the 4th volume-based purchase (VBP) was issued to clarify the relevant varieties and rules, and the bidding will start on February 3rd, 2021.
Biobanks and vaccines are the main driving force for the overall cryogenic storage market to continue to grow at a high rate in the future.
Currently, the “AI + medical” industry is in a period of rapid growth.
2. Company news:News about the progress of innovative medical device, new drugs and new licensing agreement from Venus MedTech (2500 HK), Gracell Biotechnologies Inc (GRCL US), Innovent Biologics Inc (1801 HK), and Alphamab Co Ltd (9966 HK).3. Market review: Last week, stock price for healthcare sector in A share increased 7.79%, while CSI 300 increased 2.05% over the same period of time.4. Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China

Qingdao Haier Biomedical Co., Ltd. designs, manufacture, and markets low temperature storage equipment for biomedical samples. The Company provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies, and reagent safety as well. Qingdao Haier Biomedical

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Qingdao Haier Biomedical Lt (688139 CH)

Haier Biomedical (688139.CH) - Just Been Included in the FTSE GEIS, Time to Follow

This article analyzed Haier Biomedical in terms of market potential, business analysis (technology advantage, competitive strength, development of...

Xinyao (Criss) Wang

China Healthcare Weekly (Jan.22)

The article analyzed the new official document for the volume-based purchase,industry viewpoints on China cryogenic storage market and “AI +...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)